Intra-Cellular Therapies, Inc.

201 articles about Intra-Cellular Therapies, Inc.

• Intra-Cellular Therapies Reports First Quarter 2023 Financial Results and Provides Corporate Update

  5/4/2023

  Intra-Cellular Therapies, Inc. today announced its financial results for the first quarter ended March 31, 2023 and provided a corporate update.

• Intra-Cellular Therapies to Present at Two Upcoming May 2023 Investor Conferences

  5/2/2023

  Intra-Cellular Therapies, Inc., a biopharmaceutical company focused on the development and commercialization of therapeutics for central nervous system disorders, announced that it will present at two upcoming investor conferences.

• Intra-Cellular Therapies to Host First Quarter 2023 Financial Results Conference Call and Webcast

  4/26/2023

  Intra-Cellular Therapies, Inc. (Nasdaq: ITCI) today announced it will host a conference call and live webcast discussion at 8:30 a.m. Eastern Time on Thursday, May 4, 2023, to provide a corporate update and discuss details of the Company's financial results for the quarter ended March 31, 2023.

• Intra-Cellular Therapies to Present at the 22nd Annual Needham Virtual Healthcare Conference

  4/11/2023

  Intra-Cellular Therapies, Inc. announced that Sharon Mates, Ph.D., Chief Executive Officer and Chairman, is scheduled to present at the 22nd Annual Needham Virtual Healthcare Conference on Tuesday, April 18, 2023 at 11:45 a.m. ET.

• 

  Positive Phase III Builds Case for Intra-Cellular's Depression Drug

  3/29/2023

  Intra-Cellular Therapies’ Caplyta met its primary endpoint in the Phase III Study 403 trial, easing the burden of depressive episodes in patients with major depressive disorder or bipolar depression.

• Intra-Cellular Therapies Reports Fourth Quarter and Full-Year 2022 Financial Results and Provides Corporate Update

  3/1/2023

  Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central nervous system (CNS) disorders, today announced its financial results for the fourth quarter and year ended December 31, 2022 and provided a corporate update.

• Intra-Cellular Therapies to Host Fourth Quarter and Full Year 2022 Financial Results Conference Call and Webcast

  2/14/2023

  Intra-Cellular Therapies, Inc. (Nasdaq: ITCI) today announced it will host a conference call and live webcast discussion at 8:30 a.m. Eastern Time on Wednesday, March 1, 2023, to provide a corporate update and discuss details of the Company's financial results for the quarter and year ended December 31, 2022.

• Intra-Cellular Therapies to Present at the SVB Securities Global Biopharma Conference

  2/8/2023

  Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central nervous system (CNS) disorders, today announced that Sharon Mates, Ph.D., Chief Executive Officer and Chairman, is scheduled to present at the SVB Securities Global Biopharma Conference on Wednesday, February 15, 2023 at 10:40 a.m. ET.

• Intra-Cellular Therapies to Present at the 41st Annual J.P. Morgan Healthcare Conference

  1/3/2023

  Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central nervous system (CNS) disorders, today announced that Sharon Mates, Ph.D., Chief Executive Officer and Chairman, is scheduled to present at the 41st Annual J.P. Morgan Healthcare Conference on Monday, January 9, 2023 at 11:15 a.m. PT.

• Intra-Cellular Therapies Highlights New CAPLYTA Bipolar Depression Data Presentations at the American College of Neuropsychopharmacology 61st Annual Meeting

  12/8/2022

  Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central nervous system (CNS) disorders, today announced four data presentations at the American College of Neuropsychopharmacology (ACNP) 61st Annual Meeting highlighting the therapeutic use of CAPLYTA for the treatment of bipolar I and II depression.

• Intra-Cellular Therapies to Participate at Two Upcoming Investor Conferences

  11/10/2022

  Intra-Cellular Therapies, Inc. today announced that it will participate at two upcoming investor conferences: J.P. Morgan Equity Opportunities Forum Monday, November 14 – Tuesday, November 15, 2022 in Miami, FL Evercore ISI 5th Annual HealthCONx Virtual Conference Tuesday, November 29, 2022.

• Intra-Cellular Therapies Reports Third Quarter 2022 Financial Results and Provides Corporate Update

  11/3/2022

  Intra-Cellular Therapies, Inc. announced its financial results for the third quarter ended September 30, 2022 and provided a corporate update.

• Intra-Cellular Therapies to Host Third Quarter 2022 Financial Results Conference Call and Webcast

  10/27/2022

  Intra-Cellular Therapies, Inc. (Nasdaq: ITCI) today announced that it will host a conference call and live webcast discussion at 8:30 a.m. Eastern Time on Thursday, November 3, 2022, to provide a corporate update and discuss details of the Company's financial results for the quarter ended September 30, 2022.

• Intra-Cellular Therapies Reports Second Quarter 2022 Financial Results and Provides Corporate Update

  8/9/2022

  Intra-Cellular Therapies, Inc. today announced its financial results for the second quarter ended June 30, 2022 and provided a corporate update.

• Intra-Cellular Therapies to Host Second Quarter 2022 Financial Results Conference Call and Webcast

  8/2/2022

  Intra-Cellular Therapies, Inc. today announced that it will host a conference call and live webcast discussion at 8:30 a.m. Eastern Time on Tuesday, August 9, 2022, to provide a corporate update and discuss details of the Company's financial results for the quarter ended June 30, 2022.

• 

  Clinical Catch-Up: AbbVie and Genmab, Intra-Cellular, Sanofi and GSK

  6/20/2022

  Genmab and AbbVie announce positive data in large b-cell lymphoma, Intra-Cellular's bipolar depression candidate hits the endpoint in Phase III and more.

• Intra-Cellular Therapies Highlights Lumateperone Bipolar Depression Data Presentations at the 2022 International Society for Bipolar Disorders (ISBD) Experience

  6/13/2022

  Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central nervous system (CNS) disorders, today announced data presentations at the 2022 International Society for Bipolar Disorders (ISBD) Experience held virtually June 10-12, 2022.

• Intra-Cellular Therapies Reports First Quarter 2022 Financial Results and Provides Corporate Update

  5/10/2022

  Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central nervous system (CNS) disorders, today announced its financial results for the first quarter ended March 31, 2022 and provided a corporate update.

• Intra-Cellular Therapies to Host First Quarter 2022 Financial Results Conference Call and Webcast

  5/3/2022

  Intra-Cellular Therapies, Inc. announced that it will host a conference call and live webcast discussion at 8:30 a.m. Eastern Time on Tuesday, May 10, 2022, to provide a corporate update and discuss details of the Company's financial results for the quarter ended March 31, 2022.

• Intra-Cellular Therapies Announces FDA Approval of New Dosage Strengths for CAPLYTA® (lumateperone) for Specific Patient Populations

  4/25/2022

  Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), today announced that the U.S. Food and Drug Administration (FDA) approved two new dosage strengths of CAPLYTA, 10.5 mg and 21 mg capsules, to provide dosage recommendations for patients concomitantly taking strong or moderate CYP3A4 inhibitors, and 21 mg for patients with moderate or severe hepatic impairment (Child-Pugh class B or C).